Supplement

Table S1 – Questions used to determine exposure to childhood maltreatment on mental health questionnaire. 2
Table S2 – Evidence supporting a causal role for the considered risk factors on cardiovascular disease risk 2
Table S3 – ICD codes for the included cardiovascular diseases. 2
Table S4 – Variance explained by each PGS according to the P value threshold. 3
Table S5 – Association of childhood maltreatment score with cardiovascular risk factors and disease
Table S6 – Effect modification of genetic predisposition to cardiovascular risk factors and disease by childhood maltreatment score on the additive scale at P<5x10 ⁻⁸ 4
Table S7 – Effect modification of genetic predisposition to cardiovascular risk factors and disease by childhood maltreatment score on the multiplicative scale at P<5x10 ⁻⁸
Table S8 – Sex-stratified effect modification of childhood maltreatment score on genetic predisposition to cardiovascular risk factors and disease on the additive scale at P<5x10 ⁻⁸ .
Table S9 – Sex-stratified effect modification of childhood maltreatment score on genetic predisposition to cardiovascular risk factors and disease on the multiplicative scale at P<5x10 ⁻⁸ .
Table S10 – Effect modification of genetic predisposition to cardiovascular risk factors and disease by childhood maltreatment score on the additive and multiplicative scale at P<0.05
Table S11 – Effect modification of genetic predisposition to cardiovascular risk factors and disease by childhood maltreatment score on the additive and multiplicative scale at P<0.5
Table S12 – Effect modification of genetic predisposition to cardiovascular risk factors and disease by childhood maltreatment score on the additive and multiplicative scale at P<5x10 ⁻⁸ , adjusted for covariate interactions
Table S13 – Effect modification of genetic predisposition to cardiovascular risk factors and disease by exposure to childhood maltreatment on the additive and multiplicative scale at P<5x10-8, adjusted for childhood SEP.
Methods: Polygenic Scores

Table S1 – Questions used to determine exposure to childhood maltreatment on mental health que	estionnaire.

Question: "When I was a child"	Type of maltreatment	Cut-off *
"I felt loved"	Emotional neglect	2 or lower
"People in my family hit me so hard that it left me with bruises or marks"	Physical abuse	1 or higher
"I felt that someone in my family hated me"	Emotional abuse	1 or higher
"Someone molested me (sexually)"	Sexual abuse	1 or higher
"There was someone to take me to the doctor if I needed it"	Physical neglect	3 or lower

*According to the following answers: 0: never true; 1: rarely true; 2: sometimes true; 3: often true; 4: very often true.

Table S2 – Evidence supporting a causal role for the considered risk factors on cardiovascular disease risk

Risk factor	Study	Study design			
Alcohol (drinks per week)	Millwood <i>et al,</i> 2019 ¹	Mendelian randomization study			
BMI	Carter et al, 2019 ² ; Larsson et al, 2020 ³	Mendelian randomization study; Mendelian randomization study			
Low density lipoprotein cholesterol	Ference et al, 2017 ⁴ ; Cheung et al, 2004 ⁵	Mendelian randomization and clinical study; randomized controlled trial			
Smoking (lifetime behaviour)	Larsson et al, 2020 ⁶	Mendelian randomization study			
Systolic blood pressure	Carter <i>et al,</i> 2019 ² ; Ettehad <i>et al,</i> 2016 ⁷	Mendelian randomization study; systematic review including randomized controlled trial			
Type 2 diabetes	Ahmad <i>et al,</i> 2015 ⁸	Mendelian randomization study			

Table S3 – ICD codes for the included cardiovascular diseases/risk factors.

Diagnosis	ICD9	ICD10
Atrial Fibrillation	427.31	148
Type 2 diabetes	250.00, 250.02, 250.10, 250.12,	E11
	250.20, 250.22, 250.30, 250.32,	
	250.40, 250.42, 250.50, 250.52,	
	250.60, 250.62, 250.70, 250.72,	
	250.80, 250.82, 250.90, 250.92	
Coronary Heart Disease	410.0-414.9	120-125
Stroke	430.0-438.9	G45, I60-I64

Risk factor/disease	P<5×10 ⁻⁸		P<0.05		P<0.5		
GWAS	# of SNPs	R ²	# of SNPs	R ²	# of SNPs	R ²	
BMI	127	0.02983	20 542	0.06512	139 582	0.06868	
Drinks per week	14	0.07834	72 962	0.08039	449 080	0.08019	
LDL cholesterol	398	0.07026	13 337	0.02450	23 724	0.02288	
Lifetime smoking (sample 1)	23	0.00621	67 741	0.01571	391 104	0.01606	
Lifetime smoking (sample 2)	21	0.00641	66 909	0.01516	390 557	0.01559	
Systolic blood pressure (sample 1)	126	0.15067	77 709	0.17562	373 402	0.17260	
Systolic blood pressure (sample 2)	112	0.14150	76 557	0.16176	372 715	0.16011	
Atrial Fibrillation	3431	0.09755	60 738	0.29849	361 969	0.38717	
Type 2 Diabetes	18	0.02916	5 137	0.02422	134 673	0.02300	
Coronary Heart Disease	75	0.06554	49 098	0.06453	345 040	0.06356	
Stroke	11	0.03919	63 025	0.03948	373 240	0.03919	

Table S4 – Variance explained by each PGS according to the P value threshold.

Table 55 – Association of childhood maltreatment score with cardiovascular risk factors and disease. Analyses were adjusted for age and sex.

Continuous trait	Mean difference in SD of phenotypic trait per unit increase in maltreatment score (95% CI)
BMI	0.068 (0.062, 0.073)
Drinks per week	0.002 (-0.003, 0.008)
LDL cholesterol	0.003 (-0.003, 0.009)
Lifetime smoking	0.101 (0.095, 0.107)
Systolic blood pressure	-0.011 (-0.017, -0.005)
Binary trait	Odds ratio per unit increase in maltreatment score (95% CI)
Atrial Fibrillation	1.04 (0.99, 1.08)
Type 2 Diabetes	1.19 (1.14, 1.25)
Coronary Heart Disease	1.13 (1.10, 1.17)
Stroke	1.06 (1.00, 1.12)

Table S6 – Effect modification of genetic predisposition to cardiovascular risk factors and disease by childhood maltreatment score on the additive scale at P<5x10⁻⁸. Analyses were adjusted for age, sex and 40 genetic principal components.

			Additive scale							
Continuous N trait N		1	Mean difference in SD of trait per SD increase of PGS (95% CI)	Mean difference in SD of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value for interaction				
BMI	100659		0.12 (0.11, 0.13)	0.065 (0.060, 0.071)	0.009 (0.003, 0.014)	0.003				
Drinks per week	100529		0.04 (0.04, 0.05)	0.001 (-0.004, 0.007)	0.002 (-0.004, 0.007)	0.598				
LDL cholesterol	95809		0.23 (0.22, 0.23)	0.003 (-0.002, 0.009)	0.003 (-0.002, 0.009)	0.238				
Lifetime smoking	95845		0.04 (0.03, 0.04)	0.100 (0.094, 0.105)	0.003 (-0.003, 0.008)	0.395				
Systolic blood pressure	93001		0.09 (0.08, 0.10)	-0.011 (-0.016, -0.005)	-0.002 (-0.008, 0.004)	0.490				
Binary trait	N = 100833		Risk difference of trait per SD increase of PGS (95% Cl)	Risk difference of trait per SD increase of maltreatment score (95% CI)	Interaction coefficient	P value for interaction				
	Control	98735								
Atrial fibrillation	Case	2098	0.011 (0.010, 0.012)	0.001 (0.000, 0.002)	4x10 ⁻⁴ (-4x10 ⁻⁴ , 1x10 ⁻³)	0.322				
Tuna 2 diabatas	Control	99449	0.003 (0.003, 0.004)	0.003 (0.002, 0.003)	4x10 ⁻⁴ (-2x10 ⁻⁴ , 1x10 ⁻³)	0.196				
Type 2 diabetes	Case	1384	0.003 (0.003, 0.004)	0.003 (0.002, 0.003)	4,10 (-2,10,1,1,10)	0.190				
Coronary heart	Control	97801	0.007 (0.006, 0.008)	0.004 (0.003, 0.005)	3x10 ⁻⁴ (-1 x10 ⁻³ , 1x10 ⁻³)	0.611				
disease	Case	3032	0.007 (0.000, 0.000)	0.000 (0.000)	5/10 (1/10 , 1/10)	0.011				
Stroke	Control	99838	1x10 ⁻⁴ (-5x10 ⁻⁴ , 8x10 ⁻⁴)	0.001 (-0.000, 0.001)	1x10 ⁻⁵ (-5x10 ⁻⁴ , 6x10 ⁻⁴)	0.973				
	Case	995			(),),),),),),),),),),),),),					

eTable 7 – Effect modification of genetic predisposition to cardiovascular risk factors and disease by childhood maltreatment score on the multiplicative scale at P<5x10⁸. Analyses were adjusted for age, sex and 40 genetic principal components.

			Multiplicative scale						
Continuous trait	Ν		Mean difference in SD of log trait per SD increase of PGS (95% CI)	Mean difference in log SD of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value for interaction			
BMI	100659		0.12 (0.11, 0.13)	0.065 (0.059, 0.070)	0.007 (0.001, 0.013)	0.015			
Drinks per week	100529		0.05 (0.04, 0.06)	-0.028 (-0.033, -0.022)	0.002 (-0.004, 0.008)	0.496			
LDL cholesterol	95809		0.23 (0.22, 0.23)	0.002 (-0.003, 0.008)	0.004 (-0.002, 0.010)	0.164			
Lifetime smoking	95845		0.04 (0.03, 0.04)	0.103 (0.097, 0.109)	0.002 (-0.003, 0.008)	0.429			
Systolic blood pressure	93001		0.09 (0.09, 0.10)	-0.011 (-0.017, -0.006)	-0.002 (-0.007, 0.004)	0.506			
Binary trait	N	I	OR of trait per SD increase of PGS (95% Cl)	OR of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value for interaction			
Atrial fibrillation	Control	98735	1.69 (1.62, 1.76)	1.03 (0.98, 1.08)	1.02 (0.98, 1.06)	0.312			
	Case	2098	1.09 (1.02, 1.70)	1.03 (0.98, 1.08)	1.02 (0.98, 1.00)	0.512			
Tuna 2 diabatas	Control	99449	1 20 /1 22 1 25)	1 20 (1 14 1 25)	0.00 (0.05, 1.04)	0.740			
Type 2 diabetes	Case	1384	1.29 (1.22, 1.35)	1.20 (1.14, 1.25)	0.99 (0.95, 1.04)	0.743			
Coronary heart	Control 97801 Case 3032		1.28 (1.23, 1.32)	1.14 (1.10, 1.18)	0.99 (0.96, 1.02)	0.615			
disease			1.20 (1.23, 1.32)	1.14 (1.10, 1.10)	0.33 (0.30, 1.02)	0.615			
Stroke	Control	99838	1.02 (0.95, 1.08)	1.06 (1.00, 1.12)	1.00 (0.94, 1.06)	0.990			
JUOKE	Case	995	1.02 (0.33, 1.08)	1.00 (1.00, 1.12)	1.00 (0.94, 1.00)	0.990			

Table S8 – Sex-stratified effect modification of childhood maltreatment score on genetic predisposition to cardiovascular risk factors and disease on the additive scale at P<5x10⁻⁸. Analyses were adjusted for age, sex and 40 genetic principal components. BMI=body mass index; LDL=low-density lipoprotein; PGS=polygenic score.

						Additive scale					
Continuous trait		ı	Sex	N	Mean difference in SD of trait per SD increase of PGS (95% CI)	Mean difference in SD of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P Value for interaction	P value interaction by sex		
BMI	100659		Female	57540	0.13 (0.12, 0.14)	0.067 (0.059, 0.074)	0.007 (-0.001, 0.015)	0.071	0.500		
			Male	43119	0.11 (0.11, 0.12)	0.064 (0.056, 0.072)	0.010 (0.002, 0.019)	0.016	0.596		
Drinks per	100529		Female	57541	0.04 (0.03, 0.05)	-0.002 (-0.008, 0.004)	3E-04 (-0.006, 0.006)	0.926	0.503		
week			Male	42988	0.05 (0.04, 0.06)	0.005 (-0.005, 0.016)	0.004 (-0.006, 0.015)	0.429	0.503		
LDL cholesterol	95809		Female	54698	0.24 (0.23, 0.25)	0.009 (0.002, 0.016)	0.002 (-0.005, 0.009)	0.604	0.506		
			Male	41111	0.21 (0.20, 0.22)	-0.002 (-0.011, 0.007)	0.004 (-0.005, 0.013)	0.406	0.506		
Lifetime	time 95845		Female	54768	0.03 (0.02, 0.04)	0.095 (0.088, 0.102)	0.001 (-0.006, 0.008)	0.735	0.440		
smoking			Male 41077		0.04 (0.03, 0.05)	0.107 (0.097, 0.117)	0.006 (-0.004, 0.016)	0.258	0.440		
Systolic blood	93001	93001 Fema		53143	0.10 (0.09, 0.11)	-0.010 (-0.018, -0.003)	-0.004 (-0.011, 0.004)	0.320	0.572		
pressure		Ν		39858	0.09 (0.08, 0.10)	-0.009 (-0.018, 0.000)	-2X10 ⁻⁵ (-9x10 ⁻³ , 9x10 ⁻³)	0.972	0.372		
Binary trait			Se Female N Male N =	= 57641	Risk difference of trait per SD increase of PGS (95% Cl)	Risk difference of trait per SD increase of maltreatment score (95% CI)	Interaction coefficient	P value for interaction	P value interaction by		
Atrial	Control	98735	Female		0.007 (0.006, 0.008)	2x10 ⁻⁴ (-6x10 ⁻⁴ , 0.001)	4x10 ⁻⁴ (-4x10 ⁻⁴ , 0.001)	0.350	0.432		
fibrillation	Case	2098	Male		0.017 (0.016, 0.019)	0.002 (0.000, 0.003)	0.001 (-0.001, 0.003)	0.226	0.452		
Type 2	Control	99449	Female		0.003 (0.002, 0.004)	0.002 (0.001, 0.003)	0.001 (0.000, 0.001)	0.046	0.349		
diabetes	Case	1384	Male		0.004 (0.003, 0.005)	0.004 (0.003, 0.005)	6x10-5 (-0.001, 0.001)	0.926	0.349		
Coronary heart disease	Control	97801	Female		1 Female 0.004 (0.003, 0.005)		0.004 (0.003, 0.005)	0.003 (0.002, 0.004)	-3x10 ⁻⁴ (-1x10-3, 1x10- 3)	0.527	0.065
	Case	3032	Male		0.011 (0.009, 0.013)	0.004 (0.002, 0.006)	0.002 (-4x10 ⁻⁴ , 0.004)	0.116			
Stroke	Control	99838	Female		2x10 ⁻⁴ (-5x10 ⁻⁴ , 9x10 ⁻⁴)	0.001 (0.000, 0.001)	5x10 ⁻⁴ (-1x10 ⁻⁴ , 1x10 ⁻³)	0.106	0.020		
	Case	995	Male		1x10 ⁻⁴ (-1x10 ⁻³ , 1x10 ⁻³)	2x10 ⁻⁴ (-9x10 ⁻⁴ , 1x10 ⁻³)	-1x10 ⁻⁴ (-2x10 ⁻³ , 2x10 ⁻⁴)	0.118	0.020		

Table S9 – Sex-stratified effect modification of childhood maltreatment score on genetic predisposition to cardiovascular risk factors and disease on the multiplicative scale at P<5x10⁻⁸. Analyses were adjusted for age, sex and 40 genetic principal components. BMI=body mass index; LDL=low-density lipoprotein; PGS=polygenic score.

					Multiplicative scale						
Continuous trait		N	Sex	N	Mean difference in SD of log trait per SD increase of PGS (95% Cl)	Mean difference in log SD of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value for Interaction	P value interaction by sex		
вмі	100659		Female	57540	0.13 (0.12, 0.14)	0.066 (0.059, 0.074)	0.006 (-0.002, 0.013)	0.145	0.635		
DIVII	100059		Male	43119	0.11 (0.11, 0.12)	0.062 (0.053, 0.070)	0.009 (3x10-4, 0.017)	0.042	0.055		
Drinks per	100529		Female	57541	0.05 (0.05, 0.06)	-0.028 (-0.035, -0.021)	0.001 (-0.006, 0.008)	0.839	0.616		
week	100529		Male	42988	0.04 (0.03, 0.05)	-0.028 (-0.037, -0.019)	0.004 (-0.005, 0.013)	0.402	0.010		
LDL cholesterol	95809		Female	54698	0.24 (0.23, 0.25)	0.008 (0.001, 0.015)	0.003 (-0.004, 0.010)	0.465	0.544		
LDL CHOIESTEI OI	93809		Male	41111	0.21 (0.20, 0.21)	-0.003 (-0.013, 0.006)	0.004 (-0.005, 0.014)	0.379	0.544		
Lifetime	95845		Female	54768	0.03 (0.02, 0.04)	0.099 (0.092, 0.106)	0.002 (-0.005, 0.009)	0.620	0.672		
smoking	95645		Male	41077	0.05 (0.04, 0.06)	0.108 (0.098, 0.119)	0.004 (-0.006, 0.015)	0.396	0.072		
Systolic blood	93001		Female	53143	0.10 (0.09, 0.11)	-0.011 (-0.018, -0.004)	-0.004 (-0.011, 0.003)	0.280	0.477		
pressure	93001	001		39858	0.09 (0.08, 0.09)	-0.009 (-0.018, -0.001)	4x10-4 (-0.008, 0.009)	0.934	0.477		
Binary trait	N = 1	00 833	Sex Female N= 57641 Male N = 43192		OR of trait per SD increase of PGS (95% Cl)	OR of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value for Interaction	P value interaction by sex		
Atrial	Control	98735	Female		1.61 (1.50, 1.72)	1.00 (0.93, 1.07)	1.03 (0.97, 1.10)	0.291	0.683		
fibrillation	Case	2098	Male		1.74 (1.65, 1.84)	1.05 (0.99, 1.12)	1.01 (0.96, 1.07)	0.588	0.065		
Tupo 2 diabetes	Control	99449	Female		1.34 (1.24, 1.46)	1.18 (1.10, 1.26)	1.01 (0.95, 1.08)	0.651	0.324		
Type 2 diabetes	Case 1384		Male		1.25 (1.17, 1.33)	1.22 (1.14, 1.29)	0.97 (0.91, 1.03)	0.341	0.524		
Coronary heart	Control	97801	Female		1.23 (1.16, 1.31)	1.20 (1.14, 1.26)	0.96 (0.92, 1.01)	0.127	0.088		
disease	Case	3032	Male		1.30 (1.24, 1.36)	1.09 (1.04, 1.14)	1.02 (0.97, 1.07)	0.401	0.000		
Stroke	Control	99838	Female		1.03 (0.93, 1.13)	1.09 (1.01, 1.19)	1.06 (0.98, 1.15)	0.136	0.029		
JUOKE	Case	995	Male		1.01 (0.93, 1.10)	1.01 (0.93, 1.10)	0.94 (0.86, 1.02)	0.123	0.029		

Table S10 – Effect modification of genetic predisposition to cardiovascular risk factors and disease by childhood maltreatment score on the additive and multiplicative scale at P<0.05. Analyses were adjusted for age, sex and 40 genetic principal components. BMI=body mass index; LDL=low-density lipoprotein; PGS=polygenic score.

	P<0.05										
		Additive scal	le			Multiplicative scale					
Continuous Trait	Mean difference in SD of trait per SD increase of PGS (95% CI)	Mean difference in SD of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value of interaction	Mean difference in SD of log trait per SD increase of PGS (95% CI)	Mean difference in log SD of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value of interaction			
BMI	0.23 (0.22, 0.23)	0.061 (0.056, 0.067)	0.016 (0.010, 0.021)	2x10 ⁻ 8	0.23 (0.22, 0.23)	0.060 (0.055, 0.066)	0.013 (0.008, 0.019)	4x10 ⁻⁶			
Drinks per week	0.06 (0.06, 0.07)	0.001 (-0.005, 0.007)	-0.002 (- 0.007, 0.004)	0.465	0.06 (0.06, 0.07)	-0.028 (- 0.033, -0.022)	-0.002 (- 0.008, 0.004)	0.480			
LDL cholesterol	0.08 (0.07, 0.09)	0.003 (-0.003, 0.009)	3x10 ⁻⁴ (- 6x10 ⁻³ , 6x10 ⁻³)	0.917	0.08 (0.07, 0.09)	0.002 (-0.004, 0.008)	2x10 ⁻⁴ (-6x10 ⁻ ³ , 6x10 ⁻³)	0.941			
Lifetime smoking	0.12 (0.11, 0.13)	0.206 (0.143, 0.269)	0.017 (0.009, 0.024)	7x10 ⁻ 6	0.12 (0.12, 0.13)	0.215 (0.152, 0.278)	0.014 (0.007, 0.022)	1x10 ⁻⁴			
Systolic blood pressure	0.21 (0.20, 0.22)	0.043 (-0.017, 0.101)	-9x10 ⁻⁵ (- 7x10 ⁻³ , 6x10 ⁻³)	0.978	0.21 (0.21, 0.22)	0.037 (-0.022, 0.095)	0.001 (-0.006, 0.007)	0.223			
Binary Trait	Risk difference of trait per SD increase of PGS (95% CI)	Risk difference of trait per SD increase of maltreatment score (95% CI)	Interaction coefficient	P value of interaction	OR of trait per SD increase of PGS (95% CI)	OR of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value of interaction			
Atrial fibrillation	0.032 (0.031, 0.033)	0.001 (0.000, 0.001)	-6x10 ⁻⁴ (- 1x10 ⁻⁴ , 2x10 ⁻⁴)	0.122	4.56 (4.35, 4.79)	1.06 (0.98 <i>,</i> 1.14)	0.98 (0.93, 1.02)	0.365			
Type 2 diabetes	0.002 (0.001, 0.002)	0.003 (0.002, 0.003)	2x10 ⁻⁴ (- 5x10 ⁻⁴ , 9x10 ⁻⁴)	0.575	1.12 (1.06, 1.18)	1.20 (1.14, 1.25)	1.00 (0.95, 1.04)	0.867			
Coronary heart disease	0.006 (0.005, 0.007)	0.004 (0.003, 0.004)	-3x10 ⁻⁵ (- 1x10 ⁻³ , 1x10 ⁻³)	0.954	1.25 (1.20, 1.30)	1.13 (1.10, 1.17)	0.98 (0.95, 1.02)	0.367			
Stroke	0.001 (0.000, 0.001)	0.001 (0.000, 0.001)	-1x10-5 (- 6x10-4, 6x10 ⁻⁴)	0.960	1.06 (1.00, 1.13)	1.06 (0.99 <i>,</i> 1.12)	1.00 (0.94, 1.06)	0.953			

Table S11 – Effect modification of genetic predisposition to cardiovascular risk factors and disease by childhood maltreatment score on the additive and multiplicative scale at P<0.5. Analyses were adjusted for age, sex and 40 genetic principal components. BMI=body mass index; LDL=low-density lipoprotein; PGS=polygenic score.

	P<0.5								
		Additive scale		Multiplicative scale					
Continuous Trait	Mean difference in SD of trait per SD increase of PGS (95% CI)	Mean difference in SD of trait per unit increase of maltreatment score (95% Cl)	Interaction coefficient	P value of interaction	Mean difference in SD of log trait per SD increase of PGS (95% CI)	Mean difference in log SD of trait per unit increase of maltreatment score (95% Cl)	Interaction coefficient	P value of interaction	
ВМІ	0.23 (0.23, 0.24)	0.061 (0.055 <i>,</i> 0.066)	0.015 (0.009, 0.020)	1x10 ⁻ 7	0.24 (0.23, 0.24)	0.060 (0.054 <i>,</i> 0.066)	0.011 (0.007, 0.017)	2x10 ⁻⁵	
Drinks per week	0.06 (0.06 <i>,</i> 0.07)	0.001 (-0.005, 0.007)	-0.002 (- 0.008, 0.003)	0.467	0.06 (0.06 <i>,</i> 0.07)	-0.028 (-0.033, - 0.022)	-0.002 (- 0.008, 0.003)	0.397	
LDL cholesterol	0.07 (0.06 <i>,</i> 0.08)	0.003 (-0.003, 0.009)	0.003 (- 0.003, 0.009)	0.276	0.07 (0.06 <i>,</i> 0.07)	0.002 (-0.004, 0.008)	0.003 (- 0.003, 0.008)	0.377	
Lifetime smoking	0.14 (0.13 <i>,</i> 0.14)	0.201 (0.138, 0.264)	0.022 (0.014, 0.030)	3x10⁻ ଃ	0.14 (0.13 <i>,</i> 0.15)	0.210 (0.147, 0.273)	0.020 (0.012, 0.028)	9x10 ⁻⁷	
Systolic blood pressure	0.22 (0.21, 0.23)	0.036 (-0.023, 0.096)	0.002 (- 0.005, 0.009)	0.574	0.22 (0.22, 0.23)	0.031 (-0.028, 0.090)	0.003 (- 0.004, 0.010)	0.413	
Binary Trait	Risk difference of trait per SD increase of PGS (95% CI)	Risk difference of trait per SD increase of maltreatment score (95% Cl)	Interaction coefficient	P value of interaction	OR of trait per SD increase of PGS (95% CI)	OR of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value of interaction	
Atrial fibrillation	0.040 (0.039 <i>,</i> 0.041)	0.001 (-0.000, 0.001)	-0.001 (- 0.002, 0.000)	0.066	5.37 (5.11 <i>,</i> 5.64)	1.06 (0.97, 1.15)	0.98 (0.94, 1.03)	0.432	
Type 2 diabetes	2x10 ⁻⁴ (-5x10 ⁻ ^₄ , 9x10 ⁻⁴)	0.003 (0.002, 0.003)	2x10 ⁻⁴ (-5x10 ⁻ ⁴ , 9x10 ⁻⁴)	0.535	1.02 (0.96, 1.07)	1.20 (1.14, 1.25)	1.01 (0.97, 1.06)	0.615	
Coronary heart disease	0.006 (0.005, 0.007)	0.004 (0.003 <i>,</i> 0.005)	-1x10 ⁻⁴ (- 1x10 ⁻³ , 8x10 ⁻ ⁴)	0.782	1.22 (1.18, 1.27)	1.14 (1.10, 1.17)	0.98 (0.95, 1.02)	0.331	
Stroke	1x10 ⁻⁴ (-5x10 ⁻ ⁴ , 8x10 ⁻⁴)	0.001 (0.000, 0.001)	4x10 ⁻⁵ (-5x10 ⁻ ⁴ , 6x10 ⁻⁴)	0.901	1.02 (0.95, 1.08)	1.06 (1.00, 1.12)	1.01 (0.95, 1.07)	0.865	

Table S12 – Effect modification of genetic predisposition to cardiovascular risk factors and disease by *childhood maltreatment score on the additive and multiplicative scale at P<5x10⁻⁸, adjusted for covariate interactions.* Interactions considered were those between main confounders (age, sex, and genetic principal *components) and the polygenic scores or maltreatment scores.* Analyses were also adjusted for age, sex and 40 genetic principal components. BMI=body mass index; LDL=low-density lipoprotein; PGS=polygenic score.

	Adjusted for covariate interactions, P<5x10 ⁻⁸								
Continuous Trait	Additive scale				Multiplicative scale				
	Mean difference in SD of trait per SD increase of PGS (95% CI)	Mean difference in SD of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value of interaction	Mean difference in SD of log trait per SD increase of PGS (95% Cl)	Mean difference in log SD of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value of interaction	
BMI	0.12 (0.11, 0.13)	0.099 (0.038, 0.160)	0.007 (0.001, 0.012)	0.015	0.12 (0.11, 0.13)	0.094 (0.033, 0.155)	0.006 (-0.000, 0.011)	0.054	
Drinks per week	0.04 (0.04, 0.05)	-0.004 (- 0.063, 0.056)	0.002 (-0.004, 0.007)	0.543	0.05 (0.04 <i>,</i> 0.06)	-0.068 (-0.129, -0.008)	0.002 (-0.004, 0.007)	0.598	
LDL cholesterol	0.23 (0.22, 0.23)	0.011 (-0.050, 0.072)	0.002 (-0.004, 0.008)	0.476	0.23 (0.22, 0.23)	0.014 (-0.047, 0.076)	0.002 (-0.004, 0.008)	0.452	
Lifetime smoking	0.04 (0.03, 0.04)	0.215 (0.152, 0.279)	0.002 (-0.003, 0.008)	0.463	0.04 (0.03 <i>,</i> 0.04)	0.224 (0.161 <i>,</i> 0.287)	0.002 (-0.004, 0.008)	0.515	
Systolic blood pressure	0.09 (0.08, 0.10)	0.039 (-0.021, 0.099)	-0.002 (-0.008, 0.004)	0.395	0.09 (0.09, 0.10)	0.034 (-0.026, 0.093)	-0.003 (-0.008, 0.003)	0.366	
Binary Trait	Risk difference of trait per SD increase of PGS (95% CI)	Risk difference of trait per SD increase of maltreatment score (95% CI)	Interaction coefficient	P value of interaction	OR of trait per SD increase of PGS (95% CI)	OR of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value of interaction	
Atrial fibrillation	0.011 (0.010, 0.012)	-0.002 (- 0.011, 0.006)	0.001 (0.000, 0.002)	0.022	1.69 (1.62 <i>,</i> 1.76)	0.91 (0.54 <i>,</i> 1.56)	1.02 (0.98, 1.06)	0.284	
Type 2 diabetes	0.003 (0.003, 0.004)	0.002 (-0.005, 0.009)	4 x10 ⁻⁴ (-2x10 ⁻ ⁴ , 1x10 ⁻⁴)	0.173	1.29 (1.22, 1.35)	1.44 (0.88, 2.36)	0.99 (0.95, 1.03)	0.656	
Coronary heart disease	0.007 (0.006, 0.008)	-0.002 (- 0.012, 0.009)	0.001 (-0.000, 0.002)	0.261	1.28 (1.23, 1.32)	1.58 (1.08, 2.31)	0.99 (0.96, 1.03)	0.657	
Stroke	1x10 ⁻⁴ (-5x10 ⁻ ⁴ , 8x10 ⁻⁴)	-0.003 (- 0.009, 0.003)	5x10 ⁻⁵ (-5x10 ⁻⁴ , 6x10 ⁻⁴)	0.856	1.02 (0.95, 1.08)	0.86 (0.43, 1.72)	1.00 (0.95, 1.06)	0.887	

Table S13 – Effect modification of genetic predisposition to cardiovascular risk factors and disease by exposureto childhood maltreatment on the additive and multiplicative scale at P<5x10-8, adjusted for childhood SEP.</td>Proxies of childhood SEP utilised were number of siblings and maternal smoking. Analyses were also adjusted forage, sex and 40 genetic principal components. BMI=body mass index; LDL=low-density lipoprotein;PGS=polygenic score.

	Adjusted for childhood SEP, P<5x10 ⁻⁸								
		Additive sca	ale	Multiplicative scale					
Continuous Trait	Mean difference in SD of trait per SD increase of PGS (95% CI)	Mean difference in SD of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value of interaction	Mean difference in SD of log trait per SD increase of PGS (95% Cl)	Mean difference in log SD of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value of interaction	
BMI	0.12 (0.12, 0.13)	0.057 (0.051, 0.063)	0.010 (0.004, 0.016)	0.002	0.12 (0.12, 0.13)	0.056 (0.050, 0.062)	0.009 (0.003, 0.015)	0.006	
Drinks per week	0.04 (0.04, 0.05)	0.002 (-0.004, 0.008)	4x10 ⁻⁴ (-6x10 ⁻³ , 6x10 ⁻³)	0.905	0.05 (0.04, 0.05)	-0.025 (- 0.031, -0.019)	0.001 (-0.005, 0.007)	0.807	
LDL cholesterol	0.23 (0.22, 0.24)	2x10 ⁻⁴ (-6x10 ⁻⁴ , 6x10 ⁻⁴)	0.004 (-0.002, 0.010)	0.160	0.23 (0.22, 0.23)	-0.001 (- 0.007, 0.005)	0.005 (-0.001, 0.011)	0.091	
Lifetime smoking	0.04 (0.03, 0.04)	0.087 (0.081, 0.093)	0.003 (-0.003, 0.010)	0.269	0.04 (0.03 <i>,</i> 0.04)	0.090 (0.084 <i>,</i> 0.096)	0.004 (-0.003, 0.010)	0.249	
Systolic blood pressure	0.09 (0.09, 0.10)	-0.010 (-0.016, -0.004)	-0.001 (-0.007, 0.005)	0.776	0.09 (0.09, 0.10)	-0.011 (- 0.017, -0.005)	-0.001 (- 0.007, 0.005)	0.795	
Binary Trait	Risk difference of trait per SD increase of PGS (95% Cl)	Risk difference of trait per SD increase of maltreatment score (95% CI)	Interaction coefficient	P value of interaction	OR of trait per SD increase of PGS (95% CI)	OR of trait per unit increase of maltreatment score (95% CI)	Interaction coefficient	P value of interaction	
Atrial fibrillation	0.011 (0.010, 0.012)	0.001 (-0.000, 0.001)	0.001 (-0.000, 0.001)	0.227	1.72 (1.64, 1.79)	1.01 (0.96, 1.06)	1.03 (0.99, 1.07)	0.183	
Type 2 diabetes	0.003 (0.003, 0.004)	0.002 (0.002, 0.003)	0.001 (-0.000, 0.001)	0.082	1.29 (1.22, 1.36)	1.17 (1.12, 1.23)	1.00 (0.96 <i>,</i> 1.05)	0.865	
Coronary heart disease	0.007 (0.005, 0.008)	0.003 (0.002, 0.004)	0.001 (-0.001, 0.002)	0.320	1.27 (1.22, 1.32)	1.12 (1.08, 1.17)	1.00 (0.97, 1.04)	0.963	
Stroke	6x10 ⁻⁵ (-6x10 ⁻⁴ , 7x10 ⁻⁴)	5x10 ⁻⁴ (-1x10 ⁻⁴ , 1x10 ⁻³)	2x10 ⁻⁵ (-6 x10 ⁻ ⁴ , 6x10 ⁻⁴)	0.956	1.01 (0.94, 1.08)	1.05 (0.99, 1.12)	1.00 (0.94 <i>,</i> 1.07)	0.970	

Supplementary Methods 1: Polygenic scores (PGS)

Derivation of PGSs

Summary statistics were downloaded from MR-Base ⁹ using the R statistical package, including rs IDs, effect estimates, effect alleles and relevant study information. The 1000 Genomes Project was used to find proxy SNPs in LD (R^2 above 0.8) with SNPs not found in UK Biobank. The SNPs from MR-Base were harmonised with the SNPs from UK Biobank, aligning the effect estimates and alleles. SNPs were clumped using the European subsample of the 1000 genomes project, with $R^2 < 0.001$ and a window of 10,000 kb. PGS were calculated by multiplying the number of effect alleles for each participant in UK Biobank by the effect estimate of the SNP, then summing across all SNPs associated with each trait.

Suitable summary statistics were not available for SBP and lifetime smoking, thus a split sample GWAS of the UK Biobank was performed to generate PGSs. Briefly, the participants of the study were randomly allocated to one of two samples and a GWAS was performed on each of the samples. Summary statistics of each sample were then used to calculate PGSs for the other sample, avoiding sample overlap.¹⁰ This method has been described in detail previously.²

BMI

BMI (kg/ m^2) was calculated using the height and weight measurements collected at baseline.

We used summary statistics from the Genetic Investigation of Anthropometric Traits (GIANT) Consortium BMI GWAS on individuals of European ancestry (n=339 224),¹¹ the most recent BMI GWAS without UK Biobank participants to avoid sample overlap.

Alcohol consumption (drinks per week)

Alcohol consumption was self-reported by participants at baseline at the assessment centres. Participants were asked to report their current drinking behaviours with the options daily or almost daily, three or four times a week, once or twice a week, one to three times a month, special occasions only, never or prefer not to say. Participants with an intake of once or twice weekly and over were asked to report their weekly intake of a number of alcoholic beverages; red wine, white wine, champagne, beer, cider, spirits, fortified wine. These were summed to create a variable reflecting the number of drinks per week, in which those which reported to drink one to three times a month or less were assumed to have an intake of 0 drinks per week. This variable has been previously described elsewhere.¹²

Summary statistics from the GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) GWAS of drinks per week, as previously described,¹³ were employed to generate the PGSs. UK Biobank participants were excluded to avoid sample overlap.

LDL cholesterol

LDL cholesterol was measured from plasma samples collected from participants by enzymatic protective selection analysis on a Beckman Coulter AU5800. Measurements were excluded by UK Biobank if they did not pass the UK Biobank's quality control checks after an inadvertent dilution of samples.¹⁴

Summary statistics were taken from the Global Lipids Genetics Consortium LDL cholesterol GWAS of individuals of European ancestry (n=188,577).¹⁵

Lifetime smoking

Smoking behaviour was self-reported by participants at baseline at the assessment centres. Participants were asked about smoking status (current, former or never), age of initiation, and cigarettes smoked per day. A variable reflecting lifetime smoking behaviour was generated by combining the smoking measures into an index and a half-life constant reflecting the exponential decrease in effect of smoking at a given time on health. A detailed overview of the construction of this variable can be found elsewhere.¹⁶

For the GWAS, estimates from the statistical analyses using the two samples were meta-analysed by using the *metan* command on Stata.

Systolic blood pressure

Participant systolic blood pressure measurements were taken at baseline while attending assessment centres using an Omron HEM-7105IT blood pressure monitor. The mean of two resting blood pressure measurements was used.

For the GWAS summary statistics, estimates from the statistical analyses using the two samples were metaanalysed by using the *metan* command on Stata.

Atrial Fibrillation

Atrial fibrillation cases were determined through mortality data from the UK Biobank and linked hospital episode statistics and Scottish morbidity and mortality records, referred to jointly as hospital inpatient records. Cases were identified according to the specified ICD9 and ICD10 disease code as shown in Table S3. Date of diagnosis and date of attendance of assessment centre were compared to distinguish prevalent from incident cases.

Summary statistics were obtained from an Atrial Fibrillation GWAS of individuals of European ancestry (n=59 133, of which 6 707 with atrial fibrillation).¹⁷

Type 2 Diabetes

T2DM cases were determined through mortality data from the UK Biobank and linked hospital inpatient records. Date of diagnosis and date of attendance of assessment centre were compared to distinguish prevalent from incident cases. Given the relatively low proportion of hospitalisation episodes attributed to T2DM alone, self-reported cases to UK Biobank nurses at an assessment centre were included. Cases reported at baseline were identified as prevalent if reported at baseline and as incident if reported at a follow-up visit to the assessment centre, though only a proportion of participants attend these. These self-reported variables do not distinguish between type 1 and type 2 diabetes, yet most of these cases are expected to be of the latter.

Summary statistics were taken from the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium GWAS of individuals of European ancestry (n=159,234 of which 26,676 with T2DM).¹⁸

Coronary Heart Disease

CHD cases were determined through mortality data from the UK Biobank and linked hospital inpatient records. Cases were identified according to the specified ICD9 and ICD10 disease codes as shown in Table S3, spanning subtypes such as acute myocardial infarction and angina pectoris. Date of diagnosis and date of attendance of assessment centre were compared to distinguish prevalent from incident cases.

Summary statistics were taken from the most recent CHD GWAS without UK Biobank participants. The GWAS included individuals of predominantly (77%) European ancestry (n=184,305, of which 60,801 with CHD). ¹⁹

Stroke

Stroke cases were determined through mortality data from the UK Biobank and linked hospital inpatient records. Cases were identified according to the specified ICD9 and ICD10 disease code as shown in Table S3. Date of diagnosis and date of attendance of assessment centre were compared to distinguish prevalent from incident cases.

Summary statistics were obtained from the MEGASTROKE Consortium GWAS including individuals European ancestry (n=446,696, of which cases = 40,585).²⁰

References

- 1. Millwood IY, Walters RG, Mei XW, et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. *Lancet*. 2019;393(10183):1831-1842. doi:10.1016/S0140-6736(18)31772-0
- 2. Carter AR, Gill D, Davies NM, et al. Understanding the consequences of education inequality on cardiovascular disease: Mendelian randomisation study. *BMJ*. 2019;365:1-12. doi:10.1136/bmj.l1855
- 3. Larsson SC, Bäck M, Rees JMB, Mason AM, Burgess S. Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study.

Eur Heart J. 2020;41(2):221-226. doi:10.1093/eurheartj/ehz388

- 4. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J*. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
- 5. Cheung BMY, Lauder IJ, Lau C-P, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. *Br J Clin Pharmacol*. 2004;57(5):640-651. doi:10.1111/j.1365-2125.2003.02060.x
- 6. Larsson SC, Mason AM, Bäck M, et al. Genetic predisposition to smoking in relation to 14 cardiovascular diseases. *Eur Heart J.* 2020;41(35):3304-3310. doi:10.1093/eurheartj/ehaa193
- Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet*. 2016;387(10022):957-967. doi:10.1016/S0140-6736(15)01225-8
- Ahmad OS, Morris JA, Mujammami M, et al. A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. *Nat Commun.* 2015;6:7060. doi:10.1038/ncomms8060
- 9. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. Loos R, ed. *Elife*. 2018;7:e34408. doi:10.7554/eLife.34408
- 10. Choi SW, Mak TSH, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. *Nat Protoc.* 2020;15(9):2759-2772. doi:10.1038/s41596-020-0353-1
- 11. Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature*. 2015;518(7538):197-206. doi:10.1038/nature14177
- 12. Howe LJ, Lawson DJ, Davies NM, et al. Genetic evidence for assortative mating on alcohol consumption in the UK Biobank. *Nat Commun*. 2019;10(1). doi:10.1038/s41467-019-12424-x
- 13. Liu M, Jiang Y, Wedow R, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. *Nat Genet*. 2019;51(2):237-244. doi:10.1038/s41588-018-0307-5
- 14. UK Biobank. Biomarker assay quality procedures: approaches used to minimise systematic and random errors (and the wider epidemiological implications). 2019;(April):25.
- 15. Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. *Nat Genet*. 2013;45(11):1274-1285. doi:10.1038/ng.2797
- 16. Wootton RE, Richmond RC, Stuijfzand BG, et al. Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: A Mendelian randomisation study. *Psychol Med*. 2020;50(14):2435-2443. doi:10.1017/S0033291719002678
- 17. Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. *Nat Genet*. 2012;44(6):670-675. doi:10.1038/ng.2261
- 18. Scott RA, Scott LJ, Mägi R, et al. An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. *Diabetes*. 2017;66(11):2888-2902. doi:10.2337/db16-1253
- 19. Nikpay M, Goel A, Won HH, et al. A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet*. 2015;47(10):1121-1130. doi:10.1038/ng.3396
- 20. Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet*.

2018;50(4):524-537. doi:10.1038/s41588-018-0058-3